These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 28863804)

  • 1. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
    Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
    Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
    van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
    Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
    Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
    San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
    Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
    Madan S; Lacy MQ; Dispenzieri A; Gertz MA; Buadi F; Hayman SR; Detweiler-Short K; Dingli D; Zeldenrust S; Lust J; Greipp PR; Rajkumar SV; Kumar S
    Blood; 2011 Aug; 118(7):1763-5. PubMed ID: 21673347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
    Teh BW; Harrison SJ; Worth LJ; Thursky KA; Slavin MA
    Eur J Cancer; 2016 Nov; 67():21-37. PubMed ID: 27592069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
    Dimopoulos MA; Kaufman JL; White D; Cook G; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):163-173.e6. PubMed ID: 29456035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
    Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
    Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.